Do you continue CFTR modulator therapy in patients with extra-pulmonary manifestations of CF after lung transplant?

Yes, we do continue CFTR modulators in post-transplant patients for benefits to other organs like sinuses, GI tract, pancreas and perhaps liver. We have to modify and adjust for transplant medication for dosing and interactions. Unfortunately, there is not a large evidence base supporting this practice but due to its appeal and non-FDA-approved trial and guidelines, clinicians tend to use it in transplant patients. As an expert clinician, I have seen the benefits with this approach. There are pr...